Drug Profile
MER 4101
Alternative Names: MAS-1-Adjuvanted Seasonal Inactivated Influenza Vaccine; MER4101Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Mercia Pharma Inc
- Developer Mercia Pharma Inc; Nova Immunotherapeutics Limited
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 28 Aug 2018 No recent reports of development identified for phase-I development in Influenza-virus-infections(In the elderly, In volunteers) in USA (Parenteral)
- 04 Oct 2017 Adverse events and immunogenicity data from a phase I trial in Influenza virus infections (In volunteers, In the elderly) presented at the IDWeek 2017 (IDW-2017)
- 01 Jul 2015 Phase-I clinical trials in Influenza virus infections (In volunteers, In the elderly) in USA (Parenteral)